Currently, CAR-engineered T (CAR-T) cell products targeting tumor antigens including CD19 and B cell maturation antigen (BCMA) have received the Food and Drug Administration (FDA) approval, demonstrating remarkable efficacy in treating hematological malignancies such as B cell lymphoma and multiple myeloma (MM) and achieving significant patient outcomes (1–6). This evidence concerns the gene TNFRSF17 and B-cell non-Hodgkin lymphoma.